Donepezil was associated with improved verbal memory and processing speed compared to placebo in patients with TBI and severe ...
CPC-201 is a combination of two off-patent drugs: Pfizer and Eisai’s Alzheimer’s treatment Aricept (donepezil) and solefenacin, formerly Astellas’ overactive bladder brand Vesicare.
The FDA has since approved three drugs for the treatment of mild to moderate AD: Donepezil (Aricept) was approved in 1996, Rivastigmine (Exelon) was approved in 2000, and galantamine (Reminyl) was ...
Due to the well-known cholinergic deficit in this disease, Mori and colleagues (2012) explored the use of a cholinesterase inhibitor, donepezil, for the treatment of DLB. The authors enrolled ...
The purpose of this study is to determine if Dimebon is safe and effective in patients with mild to moderate Alzheimer’s disease on Donepezil (Aricept). Cataract removal and Alzheimer’s disease. The ...
CPC-201 is a combination of two off-patent drugs: Pfizer and Eisai’s Alzheimer’s treatment Aricept (donepezil) and solefenacin, formerly Astellas’ overactive bladder brand Vesicare.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results